Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kenvue Inc.KVUE · Entity 3098 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kenvue Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 56,975.45 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 16,036 · Balance 56,975.45 F1: Grant of Deferred Share Units ("DSUs") under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in shares of the Issuer's common stock upon termination of the Reporting Person's directorship (with each DSU representing the right to receive one share of Common Stock on the settlement date). F2: Includes DSUs acquired as dividend equivalents. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Deferred Share Units ("DSUs") under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in shares of the Issuer's common stock upon termination of the Reporting Person's directorship (with each DSU representing the right to receive one share of Common Stock on the settlement date).
F2: Includes DSUs acquired as dividend equivalents.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CVS HEALTH Corp
Report date May 31, 2021 · Filed June 02, 2021
Section 16 reporting ended · disclosed 2021-06-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 632,312.9407 |
Reported balance
After 2021-05-31 transaction · row 1
1 source rowRow 1 · 2021-05-31 · Tax withholding · Disposed 634 · Balance 632,312.9407 F1: Surrender of shares in payment of FICA taxes due upon retirement. |
Filing footnotes · ownership attribution and instrument terms
F1: Surrender of shares in payment of FICA taxes due upon retirement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 26, 2026 21:10 UTC | Kenvue Inc. KVUE · Entity 3098 | GrantDeferred Share Units · Derivative | 16,036 | $17.46 | $279,988.56 |
DisclosureSEC source: 0001944048-26-000122 · wk-form4_1779829855.xml · derivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,975.45 Underlying: Common Stock · 16,036 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units ("DSUs") under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in shares of the Issuer's common stock upon termination of the Reporting Person's directorship (with each DSU representing the right to receive one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units ("DSUs") under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in shares of the Issuer's common stock upon termination of the Reporting Person's directorship (with each DSU representing the right to receive one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units ("DSUs") under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in shares of the Issuer's common stock upon termination of the Reporting Person's directorship (with each DSU representing the right to receive one share of Common Stock on the settlement date). F2 · balance_after: Includes DSUs acquired as dividend equivalents. Read SEC document |
| May 22, 2025 Filed May 28, 2025 00:35 UTC | Kenvue Inc. KVUE · Entity 3098 | GrantDeferred Share Units · Derivative | 11,914 | $23.50 | $279,979.00 |
DisclosureSEC source: 0001944048-25-000157 · wk-form4_1748392541.xml · derivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,374.526 Underlying: Common Stock · 11,914 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units ("DSUs") acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in shares of the Issuer's common stock upon termination of the Reporting Person's directorship (with each DSU representing the right to receive one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units ("DSUs") acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in shares of the Issuer's common stock upon termination of the Reporting Person's directorship (with each DSU representing the right to receive one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units ("DSUs") acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in shares of the Issuer's common stock upon termination of the Reporting Person's directorship (with each DSU representing the right to receive one share of Common Stock on the settlement date). F2 · balance_after: Includes DSUs acquired as dividend equivalents. Read SEC document |
| May 23, 2024 Filed May 28, 2024 21:27 UTC | Kenvue Inc. KVUE · Entity 3098 | GrantDeferred Share Units · Derivative | 14,403 | $19.44 | $279,994.32 |
DisclosureSEC source: 0001944048-24-000119 · wk-form4_1716931617.xml · derivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,738.537 Underlying: Common Stock · 14,403 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units ("DSUs") acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in shares of the Issuer's common stock upon termination of the Reporting Person's directorship (with each DSU representing the right to receive one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units ("DSUs") acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in shares of the Issuer's common stock upon termination of the Reporting Person's directorship (with each DSU representing the right to receive one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units ("DSUs") acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in shares of the Issuer's common stock upon termination of the Reporting Person's directorship (with each DSU representing the right to receive one share of Common Stock on the settlement date). F2 · balance_after: Includes DSUs acquired as dividend equivalents. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 22:05 UTC | Kenvue Inc. KVUE · Entity 3098 | GrantDeferred Share Units · Derivative | 11,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001944048-23-000042 · wk-form4_1693001137.xml · derivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,854 Underlying: Common Stock · 11,854 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units acquired under the Issuer's Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units acquired under the Issuer's Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units acquired under the Issuer's Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| May 31, 2021 Filed Jun 2, 2021 20:56 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 634 | $86.44 | $54,802.96 |
DisclosureSEC source: 0001127602-21-018738 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,312.9407 F1 · shares: Surrender of shares in payment of FICA taxes due upon retirement. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:26 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 8,651 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-012779 · form4.xml · nonDerivative · entry 3 MERLO LARRY J · CIK 0001194413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,946.9407 F3 · shares: Surrender of shares in payment of taxes due upon the vesting and settlement of a restricted stock unit award on April 1, 2021. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:26 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 81,700 | $74.30 | $6,070,310.00 |
DisclosureSEC source: 0001127602-21-012779 · form4.xml · nonDerivative · entry 2 MERLO LARRY J · CIK 0001194413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 622,517.9407 F2 · shares: Surrender of shares in payment of taxes due upon the vesting and settlement of the PSUs on April 1, 2021. Read SEC document |
| March 26, 2021 Filed Mar 29, 2021 22:53 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 271,347 | $0.00 Strike: $74.29 | $0.00 |
DisclosureSEC source: 0001127602-21-012256 · form4.xml · derivative · entry 7 MERLO LARRY J · CIK 0001194413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 271,347 shares Expires 2021-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/1/2015. Read SEC document |
| March 26, 2021 Filed Mar 29, 2021 22:53 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 270,650 | $74.73 | $20,225,674.50 |
DisclosureSEC source: 0001127602-21-012256 · form4.xml · nonDerivative · entry 2 MERLO LARRY J · CIK 0001194413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,025.9407 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 Plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the Reporting Person retaining all remaining shares. F2 · price: Represents weighted average sale prices for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sales prices ranging between $74.49 and $75.73 per share. Read SEC document |
| March 26, 2021 Filed Mar 29, 2021 22:53 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 271,347 | $74.29 | $20,158,368.63 |
DisclosureSEC source: 0001127602-21-012256 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 794,675.9407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Apr 2, 2021 21:26 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 180,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-012779 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,520.9407 F1 · shares: Represents shares earned by the reporting person pursuant to certain performance stock units (the "PSUs"), which were granted to the reporting person under the Issuer's 2017 Incentive Compensation Plan on February 1, 2021. The PSUs were earned based on the attainment of certain performance metrics, which performance metrics were certified by the Management and Planning Committee of the Board of Directors of the Issuer on February 1, 2021. The PSUs vested and settled on April 1, 2021. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 22:17 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 64,350 | $0.00 Strike: $74.29 | $0.00 |
DisclosureSEC source: 0001127602-21-002274 · form4.xml · derivative · entry 7 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,347 Underlying: Common Stock · 64,350 shares Expires 2021-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/1/2015. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 22:17 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 62,893 | $77.00 | $4,842,761.00 |
DisclosureSEC source: 0001127602-21-002274 · form4.xml · nonDerivative · entry 2 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 523,328.9407 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 22:17 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 64,350 | $74.29 | $4,780,561.50 |
DisclosureSEC source: 0001127602-21-002274 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 586,221.9407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:44 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 9,803 | $55.72 | $546,223.16 |
DisclosureSEC source: 0001127602-20-013416 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,871.9407 F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a restricted stock award. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:20 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 478,711 | $58.61 Strike: $58.61 | $28,057,251.71 |
DisclosureSEC source: 0001127602-20-013221 · form4.xml · derivative · entry 6 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,711 Underlying: Common Stock · 478,711 shares Expires 2030-04-01 F2 · derivative.exercise_price: The number of shares subject to the option were calculated using a 30-day average price. F3 · derivative.exercise_date: Option becomes exercisable in four equal annual installments, commencing 4/1/2021. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:20 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 8,868 | $58.34 | $517,359.12 |
DisclosureSEC source: 0001127602-20-013221 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,054.9407 F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a restricted stock award. Read SEC document |
| April 01, 2020 Filed Apr 7, 2020 21:32 UTC Amendment | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 478,711 | $0.00 Strike: $58.34 | $0.00 |
DisclosureSEC source: 0001127602-20-013399 · form4a.xml · derivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,711 Underlying: Common Stock · 478,711 shares Expires 2030-04-01 F1 · derivative.exercise_price: This Form 4/A is being filed in order to correct the exercise price (Table II, column 2) for the stock option granted on 4/1/2020, which was reported incorrectly on the original Form 4 due to a clerical error. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:43 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 51,714 | $59.18 | $3,060,434.52 |
DisclosureSEC source: 0001127602-20-009165 · form4.xml · nonDerivative · entry 2 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,364.9407 F2 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of stock awards under the Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:43 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 114,058 | $59.18 | $6,749,952.44 |
DisclosureSEC source: 0001127602-20-009165 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,078.9407 F1 · shares: Consists of stock awarded at market price pursuant to Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 21:31 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 314,713 | $0.00 Strike: $54.53 | $0.00 |
DisclosureSEC source: 0001127602-20-001938 · form4.xml · derivative · entry 7 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 314,713 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/1/2014. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 21:31 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 266,476 | $74.79 | $19,929,740.04 |
DisclosureSEC source: 0001127602-20-001938 · form4.xml · nonDerivative · entry 2 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,020.9407 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the Reporting Person retaining all remaining shares. F2 · price: Represents weighted average sale price for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sales prices ranging between $73.99 and $75.55 per share. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 21:31 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 314,713 | $54.53 | $17,161,299.89 |
DisclosureSEC source: 0001127602-20-001938 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,496.9407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:44 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 545,419 | $54.19 Strike: $54.19 | $29,556,255.61 |
DisclosureSEC source: 0001127602-19-014641 · form4.xml · derivative · entry 6 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,419 Underlying: Common Stock · 545,419 shares Expires 2029-04-01 F2 · derivative.exercise_date: Option becomes exercisable in four equal annual installments, commencing 4/1/2020. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 20:44 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 20,858 | $54.19 | $1,130,295.02 |
DisclosureSEC source: 0001127602-19-014641 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,783.9407 F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a stock award under an incentive compensation plan. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:41 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 27,731 | $57.83 | $1,603,683.73 |
DisclosureSEC source: 0001127602-19-009276 · form4.xml · nonDerivative · entry 2 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,908.9407 F2 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a stock award under the Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:41 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 33,431 | $57.83 | $1,933,314.73 |
DisclosureSEC source: 0001127602-19-009276 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,639.9407 F1 · shares: Consists of stock awarded at market price pursuant to Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 21:17 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 166,368 | $0.00 Strike: $45.07 | $0.00 |
DisclosureSEC source: 0001127602-19-003741 · form4.xml · derivative · entry 4 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 166,368 shares Expires 2019-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/2/2013. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 21:17 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 166,368 | $64.51 | $10,732,399.68 |
DisclosureSEC source: 0001127602-19-003741 · form4.xml · nonDerivative · entry 2 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,208.9407 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. F2 · price: Represents weighted average sale price for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sales prices ranging from $62.91 and $65.29 per share. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 21:17 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 166,368 | $45.07 | $7,498,205.76 |
DisclosureSEC source: 0001127602-19-003741 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496,576.9407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:26 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 166,368 | $0.00 Strike: $45.07 | $0.00 |
DisclosureSEC source: 0001127602-19-001770 · form4.xml · derivative · entry 7 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,368 Underlying: Common Stock · 166,368 shares Expires 2019-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/2/2013. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:26 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 166,368 | $69.04 | $11,486,046.72 |
DisclosureSEC source: 0001127602-19-001770 · form4.xml · nonDerivative · entry 2 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,208.9407 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. F2 · price: Represents weighted average sale price for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sales prices ranging between $68.72 and $69.65 per share. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:26 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 166,368 | $45.07 | $7,498,205.76 |
DisclosureSEC source: 0001127602-19-001770 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496,576.9407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 21:13 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 394,091 | $62.21 Strike: $62.21 | $24,516,401.11 |
DisclosureSEC source: 0001127602-18-013795 · form4.xml · derivative · entry 6 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,091 Underlying: Common Stock · 394,091 shares Expires 2025-04-01 F2 · derivative.exercise_date: Option becomes exercisable in four equal annual installments, commencing 4/1/2019. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 21:13 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 25,498 | $62.21 | $1,586,230.58 |
DisclosureSEC source: 0001127602-18-013795 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,107.4096 F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a stock award under an incentive compensation plan. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:46 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Unit | 14,616 | $67.73 | $989,941.68 |
DisclosureSEC source: 0001127602-18-009711 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634,408.8535 F1 · shares: Consists of Stock Units awarded at market price pursuant to Issuer's 2017 Incentive Compensation Plan and its Long-Term Incentive Plan, the receipt of which the reporting person has elected to defer. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:14 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 241,150 | $0.00 Strike: $34.96 | $0.00 |
DisclosureSEC source: 0001127602-17-027494 · form4.xml · derivative · entry 8 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 241,150 shares Expires 2018-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option became exercisable in four equal annual installments, commencing 4/1/2012. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:14 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 241,150 | $83.07 | $20,032,330.50 |
DisclosureSEC source: 0001127602-17-027494 · form4.xml · nonDerivative · entry 3 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,254.5612 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. F2 · price: Represents weighted average sale price for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sale prices ranging between $82.22 and $83.68 per share. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:14 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 241,150 | $34.96 | $8,430,604.00 |
DisclosureSEC source: 0001127602-17-027494 · form4.xml · nonDerivative · entry 2 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,404.5612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2017 Filed Sep 15, 2017 20:14 UTC | CVS HEALTH Corp CVS · Entity 2884 | GiftCommon Stock | 14,163 | $77.61 | $1,099,190.43 |
DisclosureSEC source: 0001127602-17-027494 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,254.5612 Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 21:31 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 338,105 | $78.05 Strike: $78.05 | $26,389,095.25 |
DisclosureSEC source: 0001127602-17-014045 · form4.xml · derivative · entry 7 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,105 Underlying: Common Stock · 338,105 shares Expires 2024-04-03 F3 · derivative.exercise_date: Option becomes exercisable in four equal annual installments, commencing 4/3/2018. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 21:31 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock (restricted) | 43,241 | $78.05 | $3,374,960.05 |
DisclosureSEC source: 0001127602-17-014045 · form4.xml · nonDerivative · entry 3 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,116 F2 · shares: Consists of restricted stock units awarded pursuant to Issuer's 2010 Incentive Compensation Plan. Restrictions lapse 50% on 4/3/2020 and 50% on 4/3/2022. Read SEC document |
| April 02, 2017 Filed Apr 4, 2017 21:31 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 19,944 | $78.50 | $1,565,604.00 |
DisclosureSEC source: 0001127602-17-014045 · form4.xml · nonDerivative · entry 2 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,417.5612 F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a restricted stock unit award. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 21:31 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 12,906 | $78.50 | $1,013,121.00 |
DisclosureSEC source: 0001127602-17-014045 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,361.5612 F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a restricted stock unit award. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:06 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 32,722 | $80.58 | $2,636,738.76 |
DisclosureSEC source: 0001127602-17-009667 · form4.xml · nonDerivative · entry 2 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,744.5612 F2 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a stock award under the Registrant's 2010 Incentive Compensation Plan and its Long-Term Incentive Plan. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:06 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantCommon Stock | 68,255 | $80.58 | $5,499,987.90 |
DisclosureSEC source: 0001127602-17-009667 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,466.5612 F1 · shares: Consists of stock awarded at market price pursuant to Issuer's 2010 Incentive Compensation Plan and its Long-Term Incentive Plan. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:11 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 76,494 | $0.00 Strike: $36.23 | $0.00 |
DisclosureSEC source: 0001127602-17-003867 · form4.xml · derivative · entry 7 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,494 shares Expires 2017-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option became exercisable in three equal annual installments, commencing 4/1/2011. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:11 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 76,494 | $78.32 | $5,991,010.08 |
DisclosureSEC source: 0001127602-17-003867 · form4.xml · nonDerivative · entry 2 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,211.5612 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. F2 · price: Represents weighted average sale price for this trading day. Multiple sales were executed, with sales prices ranging between $77.75 and $79.10 per share. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:11 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionCommon Stock | 76,494 | $36.23 | $2,771,377.62 |
DisclosureSEC source: 0001127602-17-003867 · form4.xml · nonDerivative · entry 1 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,705.5612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2016 Filed May 6, 2016 20:26 UTC | CVS HEALTH Corp CVS · Entity 2884 | Exercise / conversionStock Option · Derivative | 38,247 | $0.00 Strike: $36.23 | $0.00 |
DisclosureSEC source: 0001127602-16-051399 · form4.xml · derivative · entry 7 MERLO LARRY J · CIK 0001194413 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,494 Underlying: Common Stock · 38,247 shares Expires 2017-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option became exercisable in three equal annual installments, commencing 4/1/2011. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.